Compare HLN & NDAQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLN | NDAQ |
|---|---|---|
| Founded | 2022 | 1971 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Investment Bankers/Brokers/Service |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7B | 50.1B |
| IPO Year | N/A | 2001 |
| Metric | HLN | NDAQ |
|---|---|---|
| Price | $9.27 | $91.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $105.62 |
| AVG Volume (30 Days) | ★ 6.6M | 2.9M |
| Earning Date | 02-26-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.94% | 1.36% |
| EPS Growth | N/A | ★ 60.10 |
| EPS | N/A | ★ 0.91 |
| Revenue | N/A | ★ $4,277,000,000.00 |
| Revenue This Year | $6.55 | $10.52 |
| Revenue Next Year | $4.42 | $8.17 |
| P/E Ratio | ★ $49.05 | $100.61 |
| Revenue Growth | N/A | ★ 7.87 |
| 52 Week Low | $8.71 | $77.09 |
| 52 Week High | $11.42 | $101.79 |
| Indicator | HLN | NDAQ |
|---|---|---|
| Relative Strength Index (RSI) | 35.27 | 61.33 |
| Support Level | $9.01 | $85.88 |
| Resistance Level | $9.96 | $92.44 |
| Average True Range (ATR) | 0.13 | 2.27 |
| MACD | -0.01 | 0.42 |
| Stochastic Oscillator | 24.54 | 80.22 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.